Authors

Mark McCormack, Royal College of Surgeons in IrelandFollow
Hongsheng Gui, EPIGEN Consortium
Andrés Ingason, EPIGEN Consortium
Doug Speed, EPIGEN Consortium
Galen E B Wright, EPIGEN Consortium
Eunice J Zhang, EPIGEN Consortium
Rodrigo Secolin, EPIGEN Consortium
Clarissa Yasuda, EPIGEN Consortium
Maxwell Kwok, EPIGEN Consortium
Stefan Wolking, EPIGEN Consortium
Felicitas Becker, EPIGEN Consortium
Sarah Rau, EPIGEN Consortium
Andreja Avbersek, EPIGEN Consortium
Kristin Heggeli, EPIGEN Consortium
Costin Leu, EPIGEN Consortium
Chantal Depondt, EPIGEN Consortium
Graeme J Sills, EPIGEN Consortium
Anthony G Marson, EPIGEN Consortium
Pauls Auce, EPIGEN Consortium
Martin J Brodie, EPIGEN Consortium
Ben Francis, EPIGEN Consortium
Michael R Johnson, EPIGEN Consortium
Bobby P C Koeleman, EPIGEN Consortium
Pasquale Striano, EPIGEN Consortium
Antonietta Coppola, EPIGEN Consortium
Federico Zara, EPIGEN Consortium
Wolfram S Kunz, EPIGEN Consortium
Josemir W Sander, EPIGEN Consortium
Holger Lerche, EPIGEN Consortium
Karl Martin Klein, EPIGEN Consortium
Sarah Weckhuysen, EPIGEN Consortium
Martin Krenn, EPIGEN Consortium
Lárus J Gudmundsson, EPIGEN Consortium
Kári Stefánsson, EPIGEN Consortium
Roland Krause, EPIGEN Consortium
Neil Shear, EPIGEN Consortium
Colin J D Ross, EPIGEN Consortium
Norman Delanty, EPIGEN Consortium
Munir Pirmohamed, Canadian Pharmacogenomics Network for Drug Safety
Bruce C Carleton, Canadian Pharmacogenomics Network for Drug Safety
Fernando Cendes, EpiPGX Consortium
Iscia Lopes-Cendes, EpiPGX Consortium
Wei-Ping Liao, EpiPGX Consortium
Terence J O'Brien, EpiPGX Consortium
Sanjay M Sisodiya, EpiPGX Consortium
Stacey Cherny, International League Against Epilepsy Consortium on Complex Epilepsies
Patrick Kwan, International League Against Epilepsy Consortium on Complex Epilepsies
Larry Baum, International League Against Epilepsy Consortium on Complex Epilepsies
Gianpiero L. Cavalleri, Royal College of Surgeons in IrelandFollow

Peer Reviewed

1

Document Type

Article

Publication Date

23-1-2018

Funder/Sponsor

The work was supported by a grant from the European Commission (7th Framework Programme Grant 279062, EpiPGX). M.M.C. and G.L.C. are supported by Science Foundation Ireland, grant 13/CDA/2223, and an RCSI seed funding grant GA 14-1899. This project was supported by the General Research Funds (HKU7623/08M and HKU7747/07M to S.C., CUHK4466/06M to P.K.) and Health and Medical Research Fund (HMRF 01120086 to P.K.) from Hong Kong. Some results presented in this article were prepared using the HPC facilities of the University of Luxembourg. This work was partly undertaken at UCLH/UCL, which received a proportion of funding from the Department of Health's NIHR Biomedical Research Centres funding scheme (J.W.S., S.M.S.). The work was also supported by the Epilepsy Society, UK (J.W.S., S.M.S.), by the foundation “no epilep,” the German Chapter of the ILAE (DGfE) (both to H.L.). F.C. and I.L.-C. are supported by Fundação de Amparo à Pesquisa do Estado de São Paulo, Brazil, through grant 2013/07559-3. J.E.Z. and M.P. thank the NHS Chair of Pharmacogenetics programme and MRC Centre for Drug Safety Science for support in Liverpool. B.C.C. and C.J.D.R. are supported by the Canadian Institutes of Health Research (CIHR) Drug Safety and Effectiveness Network (FRN-117588), the Canada Foundation for Innovation and the Canadian Dermatology Foundation. G.E.B.W. is supported by a CIHR Fellowship.

Comments

This article is also available at http://n.neurology.org/content/90/4/e332.long

Abstract

OBJECTIVE: To characterize, among European and Han Chinese populations, the genetic predictors of maculopapular exanthema (MPE), a cutaneous adverse drug reaction common to antiepileptic drugs.

METHODS: We conducted a case-control genome-wide association study of autosomal genotypes, including Class I and II human leukocyte antigen (HLA) alleles, in 323 cases and 1,321 drug-tolerant controls from epilepsy cohorts of northern European and Han Chinese descent. Results from each cohort were meta-analyzed.

RESULTS: We report an association between a rare variant in the complement factor H-related 4 (CFHR4) gene and phenytoin-induced MPE in Europeans (p = 4.5 × 10-11; odds ratio [95% confidence interval] 7 [3.2-16]). This variant is in complete linkage disequilibrium with a missense variant (N1050Y) in the complement factor H (CFH) gene. In addition, our results reinforce the association between HLA-A*31:01 and carbamazepine hypersensitivity. We did not identify significant genetic associations with MPE among Han Chinese patients.

CONCLUSIONS: The identification of genetic predictors of MPE in CFHR4 and CFH, members of the complement factor H-related protein family, suggest a new link between regulation of the complement system alternative pathway and phenytoin-induced hypersensitivity in European-ancestral patients.

Disciplines

Life Sciences

Citation

McCormack M, Gui H, Ingason A, Speed D, Wright GB, Zhang EJ, Secolin R, Yasuda C, Kwok M, Wolking S, Becker F, Rau S, Avbersek A, Heggeli K, Leu C, Depondt C, Sills GJ, Marson AG, Auce P, Brodie MJ, Francis B, Johnson MR, Koeleman BPC, Striano P, Coppola A, Zara F, Kunz WS, Sander JW, Lerche H, Klein KM, Weckhuysen S, Krenn M, Gudmundsson LJ, Stefánsson K, Krause R, Shear N, Ross CJD, Delanty N, Pirmohamed M, Carleton BC, Cendes F, Lopes-Cendes I, Liao WP, O'Brien TJ, Sisodiya SM for the EpiPGX Consortium, Cherny S, Kwan P, Baum L, Cavalleri GL. Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients. Neurology. 2018; 90(4):e332-e341.

PubMed ID

29288229

DOI Link

10.1212/WNL.0000000000004853

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.

Included in

Life Sciences Commons

Share

COinS